Motif Neurotech

Executive Summary

Motif Neurotech is a therapeutic brain-computer interface (BCI) company developing minimally invasive, cosmetically invisible implantable devices to treat mental health conditions. Founded in 2020 and headquartered in Houston, Texas, the company's lead product, DOT, is a wireless implant designed to stimulate specific brain networks to treat treatment-resistant depression. DOT aims to offer a novel alternative for patients who do not respond to conventional therapies, leveraging real-time neural monitoring and regulation. With a focus on safety and patient comfort, Motif's technology represents a potential paradigm shift in neuromodulation, moving from bulky, visible implants to a discreet, user-friendly system. The company targets a large unmet need: approximately 30% of depression patients are treatment-resistant, and existing options like deep brain stimulation are invasive and costly.

Upcoming Catalysts (preview)

• Q3 2026FDA IDE approval for first-in-human study of DOT60% success
• Q2 2026Publication of preclinical data demonstrating safety and efficacy in animal models75% success
• TBDStrategic partnership with a major medical device or pharmaceutical company40% success